Regulatory Clearance Is No Longer Your Biggest Barrier — Reimbursement Is

Ask a software as a medical device (SaMD) team what keeps them awake and most will still say clearance. Yet the pattern across the last few years is hard to miss: products get cleared, then sit. The regulatory file closes, the launch deck goes out, and twelve months later the revenue line is still a rounding error. The barrier moved. It is now reimbursement.

Clearance got more predictable, not easy

None of this is to say regulatory work is trivial. It is to say it has become knowable. For most SaMD, the route is now well travelled: a 510(k) with a software predicate, De Novo where the intended use is genuinely novel, PMA where the risk profile demands it. Guidance on clinical decision support, on software functions, and on predetermined change control plans has turned what used to be negotiation into something closer to a checklist. Change control plans in particular mean a model can be updated post-clearance without restarting the process — a structural shift for anything adaptive.

In Europe and the UK the picture is heavier but still mappable. EU MDR pushed most software up into Class IIa or higher under Rule 11, which means a notified body, a clinical evaluation, and a queue. UKCA adds its own route and a UK Responsible Person. Slow, expensive, but not mysterious.

You can scope regulatory effort, cost it, and put a date on it. That is the definition of a solved problem in commercial planning terms.

Reimbursement has none of that structure

Clearance gives you the right to sell. It gives you no mechanism to be paid. For software that distinction is brutal, because software does not slot into the payment infrastructure that hardware inherited.

A physical device often arrives with a supply chain, a purchasing category, and a procedure code that already exists. SaMD frequently arrives with none of these. There may be no billing code that describes what it does. Where codes exist, the pathway to obtaining one runs on its own multi-year calendar, independent of and unaffected by your clearance date. Hospital add-on payment routes are narrow and time-limited. And in the meantime, the cost has to come from somewhere — usually a department budget that was set before your product existed, owned by someone who was not in the room during your clinical study.

Europe is not a single answer either. Reimbursement is decided nation by nation, by different bodies, on different evidence standards, with different timelines. A CE mark under EU MDR opens twenty-seven markets to sales and not one of them to guaranteed payment.

Payers ask questions regulators never ask

This is the gap that catches SaMD teams. A regulator asks whether the device is safe and performs as intended. A payer asks something entirely different:

Compared with what? Not against nothing — against current practice, including the clinician who already does this task reasonably well.

What does it displace? If your software adds a step without removing one, it is a cost with no offset.

What happens to the total budget? Not your price, but the downstream effect on admissions, readmissions, imaging volume, length of stay.

Who bills, and under what? A named entity, a named code, a named setting of care.

Where is the outcome evidence? Sensitivity and specificity against a reference standard satisfied your submission. It rarely satisfies a payer, who wants to know what changed for the patient and for the budget.

None of these questions appear in your regulatory file. All of them decide whether you get paid.

Collect the evidence during the study, not after it

The costly mistake is sequential thinking: clear first, then worry about payment. By the time you start, the study that could have answered the payer's questions has already been run and locked, designed solely around the regulatory endpoint.

Adding a health-economic layer to work you are doing anyway is comparatively cheap. Capture the comparator arm properly. Track time saved and where it went. Track downstream utilisation, not just diagnostic accuracy. Record workflow integration data — the number of clinician interactions, the abandonment rate, the false-positive burden on staff. Note the care setting, because payment often depends on it. Running that instrumentation alongside your validation costs a fraction of running a separate economic study two years later, under pressure, with a burn rate.

Run the two tracks in parallel

A workable sequence for a SaMD programme looks like this:

Identify the billing route and the code question before the clinical protocol is final, so the protocol can serve both masters.

Name the economic buyer — the individual whose budget pays — separately from the clinical champion. They are rarely the same person and they are persuaded by different evidence.

Build the budget-impact model early and update it with real data as the study runs, instead of constructing it retrospectively.

Choose launch markets on payment route availability, not on regulatory ease. A market you can enter in six months but cannot be paid in for three years is worse than one that takes eighteen months and pays on arrival.

Assume evidence generation continues after clearance. Post-market data is often what converts a pilot into a contract.

Market selection is a reimbursement decision

The instinct is to sequence markets by regulatory friction: clear the easy ones, then the hard ones. That optimises for the barrier that is no longer binding. The more useful ordering asks, for each market, whether a payment route exists for a product of this archetype, how long it takes, what evidence it demands, and who holds the budget. When you rank markets that way the list usually reorders substantially — and some markets that looked attractive on regulatory grounds drop out entirely.

How MedTech Compass handles this

This is the reasoning MedTech Compass is built to support. It scores markets across regulatory route, reimbursement environment, competitive density and adoption readiness together, so the payment question carries the same weight as the clearance question at the point you choose where to go. The weights are configurable, evidence is source-linked, and the output is a ranked entry plan rather than a regulatory checklist — which is what you actually need when clearance is the part you already know how to do.